Correlation of TET2 mutations with clinical data, FAB subtypes, and chromosomal abnormalities in AML patients (n = 486)
| Variant . | Total (N = 486) . | TET2 mutation (N = 64, 13.2%) . | TET2 wild-type (N = 422, 86.8%) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 51.5 (15-90) | 68 (21-90) | 48 (15-89) | < .001 |
| Age in groups, y | < .001 | |||
| 15-20 | 23 | 0 | 23 (100) | |
| 21-30 | 57 | 3 (5.3) | 54 (94.7) | |
| 31-40 | 78 | 7 (9.0) | 71 (91.0) | |
| 41-50 | 78 | 4 (5.1) | 74 (94.9) | |
| 51-60 | 78 | 8 (10.3) | 70 (89.7) | |
| 61-70 | 78 | 15 (19.2) | 63 (80.8) | |
| 71-80 | 69 | 17 (24.6) | 52 (75.4) | |
| > 80 | 25 | 10 (40.0) | 15 (60.0) | |
| Sex | .136 | |||
| Female | 212 | 22 (10.4) | 190 (89.6) | |
| Male | 274 | 42 (15.3) | 232 (84.7) | |
| Median laboratory data (range) | ||||
| WBC, × 103/μL | 17.91 (0.12-627.8) | 43.16 (1.68-277.25) | 15.44 (0.12-627.8) | < .001 |
| Blasts, × 103/μL | 7.33 (0-456.73) | 26.53 (0-260.62) | 5.80 (0-456.73) | < .001 |
| Hemoglobin, g/dL | 8.0 (2.9-16.2) | 8.1 (3.5-16.2) | 8.0 (2.9-13.9) | .196 |
| Platelets, × 103/μL | 43 (3-802) | 33 (6-157) | 45 (3-802) | .017 |
| LDH, U/L | 855.5 (206-13 130) | 1248 (365-7930) | 823 (206-13 130) | .004 |
| FAB | ||||
| M0 | 10 | 0 | 10 (100) | .371 |
| M1 | 108 | 13 (12.0) | 95 (88.0) | .749 |
| M2 | 168 | 28 (16.7) | 140 (83.3) | .169 |
| M3 | 38 | 0 | 38 (100) | .005 |
| M4 | 121 | 20 (16.5) | 101 (83.5) | .290 |
| M5 | 21 | 3 (14.3) | 18 (85.7) | .748 |
| M6 | 11 | 0 | 11 (100) | .375 |
| Undetermined | 9 | 0 | 9 (100) | |
| Karyotype* SWOG | ||||
| Favorable | 96 | 5 (5.2) | 91 (94.8) | .007 |
| Intermediate | 244 | 45 (18.5) | 198 (81.5) | < .001 |
| Unfavorable | 128 | 11 (8.6) | 117 (91.4) | .091 |
| Normal karyotype | 218 | 39 (18.0) | 178 (82.0) | .006 |
| Isolated trisomy 8 | 17 | 6 (35.3) | 11 (64.7) | .017 |
| Variant . | Total (N = 486) . | TET2 mutation (N = 64, 13.2%) . | TET2 wild-type (N = 422, 86.8%) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 51.5 (15-90) | 68 (21-90) | 48 (15-89) | < .001 |
| Age in groups, y | < .001 | |||
| 15-20 | 23 | 0 | 23 (100) | |
| 21-30 | 57 | 3 (5.3) | 54 (94.7) | |
| 31-40 | 78 | 7 (9.0) | 71 (91.0) | |
| 41-50 | 78 | 4 (5.1) | 74 (94.9) | |
| 51-60 | 78 | 8 (10.3) | 70 (89.7) | |
| 61-70 | 78 | 15 (19.2) | 63 (80.8) | |
| 71-80 | 69 | 17 (24.6) | 52 (75.4) | |
| > 80 | 25 | 10 (40.0) | 15 (60.0) | |
| Sex | .136 | |||
| Female | 212 | 22 (10.4) | 190 (89.6) | |
| Male | 274 | 42 (15.3) | 232 (84.7) | |
| Median laboratory data (range) | ||||
| WBC, × 103/μL | 17.91 (0.12-627.8) | 43.16 (1.68-277.25) | 15.44 (0.12-627.8) | < .001 |
| Blasts, × 103/μL | 7.33 (0-456.73) | 26.53 (0-260.62) | 5.80 (0-456.73) | < .001 |
| Hemoglobin, g/dL | 8.0 (2.9-16.2) | 8.1 (3.5-16.2) | 8.0 (2.9-13.9) | .196 |
| Platelets, × 103/μL | 43 (3-802) | 33 (6-157) | 45 (3-802) | .017 |
| LDH, U/L | 855.5 (206-13 130) | 1248 (365-7930) | 823 (206-13 130) | .004 |
| FAB | ||||
| M0 | 10 | 0 | 10 (100) | .371 |
| M1 | 108 | 13 (12.0) | 95 (88.0) | .749 |
| M2 | 168 | 28 (16.7) | 140 (83.3) | .169 |
| M3 | 38 | 0 | 38 (100) | .005 |
| M4 | 121 | 20 (16.5) | 101 (83.5) | .290 |
| M5 | 21 | 3 (14.3) | 18 (85.7) | .748 |
| M6 | 11 | 0 | 11 (100) | .375 |
| Undetermined | 9 | 0 | 9 (100) | |
| Karyotype* SWOG | ||||
| Favorable | 96 | 5 (5.2) | 91 (94.8) | .007 |
| Intermediate | 244 | 45 (18.5) | 198 (81.5) | < .001 |
| Unfavorable | 128 | 11 (8.6) | 117 (91.4) | .091 |
| Normal karyotype | 218 | 39 (18.0) | 178 (82.0) | .006 |
| Isolated trisomy 8 | 17 | 6 (35.3) | 11 (64.7) | .017 |
FAB indicates French-American-British; and LDH, lactate dehydrogenase.
Only 468 patients had available cytogenetic data at diagnosis (62 TET2-muted patients and 406 TET2-wild patients).